TLN2 (talin 2) is a cytoskeletal protein and major focal adhesion component that links integrin receptors to the actin cytoskeleton, playing a critical role in cell adhesion and cytoskeletal organization 1. As one of two mammalian talin isoforms, TLN2 shows distinct expression patterns with highest levels in heart tissue and produces multiple transcripts, contrasting with the ubiquitously expressed TLN1 2. Mechanistically, TLN2 undergoes post-translational modifications including deubiquitination by OTUB1, which stabilizes the protein and is potentiated by mechanical loading 3. Clinically, TLN2 dysfunction associates with multiple diseases. In facet joint osteoarthritis, elevated TLN2 promotes extracellular matrix degradation and upregulates the inflammatory mediator CCL2 3. Male-specific genetic epistasis between TLN2 and WWC1 (KIBRA) contributes to Alzheimer's disease risk, with both genes modulating tau toxicity in functional studies 4. TLN2 hypomethylation associates with ischemic stroke and may regulate endothelial cell adhesion 5. Conversely, TLN2 inhibition shows therapeutic promise, reducing myofibroblast differentiation and reversing bleomycin-induced lung fibrosis and kidney fibrosis in mice 6. TLN2 variants also modify disease severity in congenital heart defects by suppressing TPM1 lethality 7. These findings identify TLN2 as a multifunctional adhesion protein with significant disease relevance across degenerative, neurological, and fibrotic conditions.